Methods of treating fibrosis, cancer and vascular injuries
Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Patents(United States)
- Current Assignee / Owner
- EWHA UNIV IND COLLABORATION FOUND
- Publication Date
- 2018-11-27
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 12 / 826,338 filed Jun. 29, 2010 entitled “2-Pyridyl Substituted Imidazoles as Therapeutic ALK5 and / or ALK 4 Inhibitors”, the disclosure of which is incorporated herein by reference.
[0002] This application is a reissue of U.S. Pat. No. 8,513,222 B2, which issued from U.S. patent application Ser. No. 13 / 168,342, filed on Jun. 24, 2011.TECHNICAL FIELD OF THE INVENTION
[0003] This invention relates to use of inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and / or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.BACKGROUND OF THE INVENTION
[0004] TGF-β denotes a family of proteins, TGF-β1, TGF-β2 and TGF-β3, which are pleiotropic modulators of cell proliferation and differentiation, wound healing, extracellular matrix production, and immunosuppression. Other members of this superfamily include activins, inhibins, bone m...